FEATURED EDITORIAL
By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update
- There's A Gap In Brain Tumor Research — Here's How We Fix It
- Lessons Learned While Taking Glioblastoma Drug From Bench To Clinic
- Next‑Generation Omics: Latest Insights From A Growing Field
- AI Drug Discovery Is Revealing The Preclinical Bottleneck
- Beyond Biologics: A Biophysical Approach To Crohn's Disease
- Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
FEATURED APPLICATION CONTENT
-
Accurate serial dilutions depend on more than calculations. Learn how mixing, tip handling, and workflow consistency influence accuracy, as well as how small adjustments can improve reproducibility.
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
- Next‑Generation Omics: Latest Insights From A Growing Field
- 5 Takeaways From The Boston Open Science & Innovation Forum
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Global First | NMPA Accepts IND Application For Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
- Litmys And Konovo Form Partnership To Revolutionize Drug Development Intelligence For Life Sciences Companies
- Biointron Launches Comprehensive Antibody Developability Assessment Platform To Accelerate Biologic Drug Discovery
- Lantern Pharma Launches WithZeta.ai — The World's First Multi-Agentic A.I. Co-Scientist For Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events At Nasdaq MarketSite On 4/16 And At AACR 2026 From 4/17 To 4/22
- Novo Nordisk And OpenAI Partner To Transform How Medicines Are Discovered And Delivered
- Spirographic AI LLC Launches Tissue-Specific Polypharmacology Platform Demonstrating Industry-Leading Drug Target Prediction Accuracy
- Praxis Precision Medicines Announces FDA Acceptance Of New Drug Application For Ulixacaltamide HCl In Patients With Essential Tremor
- Vasa Therapeutics Partners With Lilly TuneLab To Power AI/ML-Driven CAMKII Inhibitor Platform
- Labcorp Introduces AI-Powered Real-World Data Platform With AWS And Datavant To Accelerate Alzheimer's Research
- Kazia Therapeutics Expands Oncology Platform With First-In-Class SETDB1 Inhibitor Drug Development Platform
ARCHIVED NEWSLETTER
- 04.14.26 -- Next Generation Omics: Latest Insights From A Growing Field
- 04.07.26 -- What If The U.S. Government Stopped Funding Biotech?
- 04.04.26 -- Drug Discovery Online Best Of March
- 03.31.26 -- AI For NAM-Ready Drug Development: Turning Promise Into Trust
- 03.24.26 -- 5 Takeaways From The Boston Open Science & Innovation Forum
